Sun Pharma introduces generic rivastigmine capsules in U.S. market

Sun Pharma announced launch of generic Exelon^®, rivastigmine tartrate capsules for the US market. Earlier, USFDA had granted final approval for the Company's ANDA to market these products.

These generic rivastigmine capsules are therapeutically equivalent of Novartis Exelon^® Capsules and include four strengths: 1.5 mg (base), 3 mg (base), 4.5 mg (base) and 6 mg (base). These strengths of Exelon® have annual sales of approximately USD 130 million in the US.

Sun Pharma, being one of the first-to-file an ANDA for generic Exelon^® with a para IV certification, shares a 180-day marketing exclusivity.

Rivastigmine tartrate is indicated for the treatment of mild to moderate dementia of the Alzheimer's type and for the treatment of mild to moderate dementia associated with Parkinson's disease.